Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma Clinical research trials and Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma. Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma clinical trial. Test subjects typically receive the most effective healthcare possible for their Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma

Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma



Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma

For Condition: Leukemia,Lymphoma,Eye Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: Patient Abstract available in the near future.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of carbendazim in patients with advanced solid tumors or lymphoma. II. Determine the qualitative and quantitative toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients. IV. Determine the recommended phase II dose of this drug. V. Determine any antitumor effects of this drug in these patients. PROTOCOL OUTLINE: This is a dose-escalation, multicenter study. Patients receive oral carbendazim 2-3 times daily 5 days a week for 3-4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of carbendazim until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 30 days. PROJECTED ACCRUAL: Approximately 30-60 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed advanced solid tumor for which no standard therapy exists or which has progressed or recurred after prior therapy OR Lymphoma for which no further therapeutic options exist - No hematological malignancies (e.g., leukemia) - No known brain or leptomeningeal disease unless previously treated with radiotherapy, not currently treated with corticosteroid therapy, and no clinical symptoms present --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: Recovered from prior chemotherapy for cancer; No other concurrent cytotoxic therapy - Endocrine therapy: See Disease Characteristics - Radiotherapy: See Disease Characteristics; Recovered from prior radiotherapy for cancer - Surgery: Recovered from prior surgery for cancer; Prior gastrointestinal surgery allowed --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 12 weeks - Hematopoietic: Absolute neutrophil count at least 1,000/mm3; Hemoglobin at least 9 g/dL; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 2 mg/dL; AST or ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if due to tumor involvement); Alkaline phosphatase less than 2.5 times ULN - Renal: Creatinine no greater than 2 mg/dL OR Creatinine clearance at least 60 mL/min - Cardiovascular: No unstable atrial or ventricular arrhythmias that require control by medication; No ischemic event within the past 6 months Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; Abnormalities that would affect absorption of study drug allowed at investigator's discretion; No other severe disease or psychiatric disorder that would preclude study; No phenylketonuria; No known hypersensitivity reaction to artificial sweetener aspartame (e.g., Nutrasweet)
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
LeeRosen,  Study Chair,  Jonsson Comprehensive Cancer Center


Additional Information:
Study ID Numbers:  CDR0000068867;  UCLA-0002007,ILEX-FB-642-103-A4,NCI-G01-2006
Study Start Date: 
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023816

Other Leukemia Studies:
1. Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

2. Flavopiridol in Treating Patients With Refractory Cancer

3. Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

4. ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

5. PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

Related Studies:

Other Leukemia Clinical Trials
Other Clinical Trials
Other Clinical Trials

Phase I Study of Carbendazim in Patients With Advanced Solid Tumors or Lymphoma
Modify your Search

  Other Leukemia Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103